Efficacy of Bisphosphonates Against Osteoporosis in Adult Men: a Meta-analysis of Randomized Controlled Trials

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2015 May 7

PMID 25944731

Citations 4

Authors

L Chen

G Wang

F Zheng

H Zhao

H Li

Affiliations

Soon will be listed here.

Abstract

Unlabelled: This meta-analysis of published randomized controlled trials (RCTs) aimed to analyze the efficacy of administration of bisphosphonates in men with osteoporosis. Compared with placebo, bisphosphonates could reduce the risk of vertebral and non-vertebral fractures, reduce bone-specific alkaline phosphatase (BSAP) and C-terminal telopeptide of type I collagen (CTX), and increase bone mineral density (BMD).

Introduction: Bisphosphonates are well-investigated antiresorptive medications, approved as first-line drugs for osteoporosis in postmenopausal women. However, there is a paucity of high-quality evidence regarding the efficacy of bisphosphonates administered for osteoporosis in adult men. The aim of this meta-analysis was to analyse the efficacy of administration of bisphosphonates in men based on published RCTs.

Methods: PubMed, Embase, MEDLINE, and the Cochrane library were searched, and mean differences were calculated to evaluate the efficacy of bisphosphonates on reducing the risk of vertebral and non-vertebral fracture, reducing bone-turnover biomarkers, and increasing BMD.

Results: Nine RCTs were included and the total number of participants was 2464. Compared with placebo, the efficacy of bisphosphonates on vertebral and non-vertebral fracture risk reduction was confirmed [for vertebral fracture, RR (95 % CI) 0.36 (0.24, 0.56), P < 0.01; for non-vertebral fracture, RR (95 % CI) 0.52 (0.32, 0.84), P < 0.01)] and heterogeneity was insignificant. The efficacy of bisphosphonates on reducing BSAP [MD (95 % CI) -24.41 (-26.19, -22.62), P < 0.01) and CTX [MD (95 % CI) -34.51 (-41.03, -27.98), P < 0.01)] was significant. A sensitivity analysis was applied to explain the origination of heterogeneity in analysis of decreasing of BSAP. BMD was increased in the bisphosphonates group compared with the control group at lumbar spine, femoral neck, and total hip (P < 0.01), and the heterogeneity of all comparisons was significant.

Conclusion: Compared with placebo, bisphosphonates could decrease the risk of vertebral and non-vertebral fractures, reduce BSAP and CTX, and increase BMD in men with osteoporosis.

Citing Articles

The top 50 cited publications relating to femoral shaft fractures - A bibliometric analysis of the literature.

Medlar C, Kilkenny C, Davey M, Farooq F, ODaly B J Orthop. 2025; 67:88-93.

PMID: 39902144 PMC: 11787685. DOI: 10.1016/j.jor.2025.01.025.

Gut microbiota and microbial metabolites for osteoporosis.

Zheng X, Wang D, Jiang Y, Song C Gut Microbes. 2024; 17(1):2437247.

PMID: 39690861 PMC: 11657146. DOI: 10.1080/19490976.2024.2437247.

Risk of first hip fracture under treatment with zoledronic acid versus alendronate: a NOREPOS cohort study of 88,000 Norwegian men and women in outpatient care.

Riska B, Gunnes N, Finnes T, Meyer H, Hoff M, Omsland T Arch Osteoporos. 2024; 19(1):102.

PMID: 39443347 PMC: 11499353. DOI: 10.1007/s11657-024-01458-4.

Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.

Shi L, Min N, Wang F, Xue Q Biomed Res Int. 2019; 2019:2594149.

PMID: 31828096 PMC: 6885847. DOI: 10.1155/2019/2594149.

Association of low testosterone with changes in non-cardiovascular biomarkers in adult men.

Samoszuk M, Morgentaler A, de Groot M, van Solinge W, Li Y, Adair F Int J Impot Res. 2019; 32(2):167-175.

PMID: 30670838 PMC: 7066050. DOI: 10.1038/s41443-019-0112-4.

References

Cosman F, de Beur S, LeBoff M, Lewiecki E, Tanner B, Randall S . Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014; 25(10):2359-81. PMC: 4176573. DOI: 10.1007/s00198-014-2794-2. View

Ringe J, Dorst A, Faber H, Ibach K . Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2003; 24(2):110-3. DOI: 10.1007/s00296-003-0388-y. View

Furlan A, Pennick V, Bombardier C, van Tulder M . 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976). 2009; 34(18):1929-41. DOI: 10.1097/BRS.0b013e3181b1c99f. View

SHIH M, COOK M, Spence C, Palnitkar S, McElroy H, Parfitt A . Relationship between bone formation rate and osteoblast surface on different subdivisions of the endosteal envelope in aging & osteoporosis. Bone. 1993; 14(3):519-21. DOI: 10.1016/8756-3282(93)90189-h. View

Saag K, Emkey R, Schnitzer T, Brown J, Hawkins F, Goemaere S . Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998; 339(5):292-9. DOI: 10.1056/NEJM199807303390502. View

Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J . Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356(18):1809-22. DOI: 10.1056/NEJMoa067312. View

Center J, Nguyen T, Schneider D, Sambrook P, Eisman J . Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999; 353(9156):878-82. DOI: 10.1016/S0140-6736(98)09075-8. View

Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H . Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. Yonsei Med J. 2009; 50(4):474-81. PMC: 2730608. DOI: 10.3349/ymj.2009.50.4.474. View

Gonnelli S, Cepollaro C, Montagnani A, Bruni D, Caffarelli C, Breschi M . Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int. 2003; 73(2):133-9. DOI: 10.1007/s00223-002-1085-7. View

10.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J . Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000; 343(9):604-10. DOI: 10.1056/NEJM200008313430902. View

11.

Boluki D . [Surgical therapy of osteoporotic vertebral body fractures]. Z Rheumatol. 2011; 70(1):45-54. DOI: 10.1007/s00393-010-0739-5. View

12.

Eriksen E, Diez-Perez A, Boonen S . Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2013; 58:126-35. DOI: 10.1016/j.bone.2013.09.023. View

13.

Sawka A, Papaioannou A, Adachi J, Gafni A, Hanley D, Thabane L . Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord. 2005; 6:39. PMC: 1182376. DOI: 10.1186/1471-2474-6-39. View

14.

Shi M, Cai X, Lin T, Wang W, Yan S . Is there really no benefit of vertebroplasty for osteoporotic vertebral fractures? A meta-analysis. Clin Orthop Relat Res. 2012; 470(10):2785-99. PMC: 3442000. DOI: 10.1007/s11999-012-2404-6. View

15.

Orwoll E, Binkley N, Lewiecki E, Gruntmanis U, Fries M, Dasic G . Efficacy and safety of monthly ibandronate in men with low bone density. Bone. 2010; 46(4):970-6. DOI: 10.1016/j.bone.2009.12.034. View

16.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

17.

Boonen S, Reginster J, Kaufman J, Lippuner K, Zanchetta J, Langdahl B . Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012; 367(18):1714-23. DOI: 10.1056/NEJMoa1204061. View

18.

Reginster J, Adami S, Lakatos P, Greenwald M, Stepan J, Silverman S . Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2005; 65(5):654-61. PMC: 1798147. DOI: 10.1136/ard.2005.044958. View

19.

Atkins D, Briss P, Eccles M, Flottorp S, Guyatt G, Harbour R . Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res. 2005; 5(1):25. PMC: 1084246. DOI: 10.1186/1472-6963-5-25. View

20.

Colin E, van den Bemd G, van Aken M, Christakos S, de Jonge H, DeLuca H . Evidence for involvement of 17beta-estradiol in intestinal calcium absorption independent of 1,25-dihydroxyvitamin D3 level in the Rat. J Bone Miner Res. 1999; 14(1):57-64. DOI: 10.1359/jbmr.1999.14.1.57. View